Sibutramine hydrochloride

Phase 3Small molecule

Sibutramine hydrochloride is one of 43 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

1 2

Colcrys

Alnylam Pharmaceuticals

Phase 3

1 3

Byetta

Zocor

2 5

Repatha

Amgen

Preclinical

5 6

Sibutramine hydrochloride

AAbbott

Phase 3

1 7

Praluent

Regeneron

Preclinical

1 8

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 9

Benicar

Novartis

Preclinical

1 10

Farxiga

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overweight1 trial

A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.

Completed·AAbbott·Phase 4·NCT00234988·93 enrolled

Cardiovascular Disease1 trial

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Completed·AAbbott·Phase 3·NCT00234832·10,777 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sibutramine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sibutramine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sibutramine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abbott company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAbbott

Sibutramine hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overweight1 trial

Cardiovascular Disease1 trial

References

Drug Info

Quick Facts

Related News